To verify whether bepristat 2a interfered with endothelial ICAM-1 expression, causing a decrease in cancer cell adhesion and transendothelial migration, hLMVECs were pre-treated with 10 ng/mL hIL-1β for 6 h, followed by treatment with bepristat 2a at various concentrations (1–50 μM) for 24 h. Here, ICAM1 is linked to cancer.